STOCK TITAN

Maravai LifeSciences Announces May and June 2022 Investor Conference Schedule

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the months of May and June.

On May 25th, 2022, at 7:45 a.m. PT, Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference being held in New York City, New York.  

On June 8th, 2022, at 8:40 a.m. PT, Mr. Herde will present at the William Blair Growth Conference being held in Chicago, Illinois.

On June 14th, 2022, at 2:40 p.m. PT, Mr. Herde will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference being held in Rancho Palos Verdes, California.

A live webcast of the presentations will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under Events and Presentations. An archived version of the webcasts will also be available on the Maravai website following the completion of each event.

About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologic safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit www.maravai.com.


Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

MRVI Rankings

MRVI Latest News

MRVI Stock Data

1.47B
98.47M
2.37%
102.51%
3.87%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About MRVI

maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri